---
title: Aren’t HOTs expensive?
description: Yes, these drugs are expensive today - especially if you lack insurance coverage in the US, but this is a temporary feature of a disruption in its early commercial phase, not a permanent characteristic of the technology.
---

[FAQ & Mythbusting ](https://www.rethinkx.com/faq-and-mythbusting)

# [Aren’t HOTs expensive?](https://www.rethinkx.com/faq-and-mythbusting/arent-hots-expensive)

 Written by [RethinkX](https://www.rethinkx.com/faq-and-mythbusting/author/admin) | Jun 2, 2026 3:02:36 PM

The price you pay for HOTs depends enormously on where in the world you live and what kind of insurance coverage you have. The range is staggering considering that the same drug, made by the same company, can cost anywhere from under $100 per month to over $1,300 per month depending on your country and coverage situation. For some patients in countries with strong national health systems and favorable reimbursement policies, GLP-1 drugs are already accessible at low or no out-of-pocket cost. For an uninsured American paying full list price, they remain among the most expensive medications on the market.

When discussing disruption, it is important to remember that price and cost are entirely different things, and the gap between them is currently enormous. Yale University researchers have shown that the manufacturing *cost* of semaglutide itself can be as low as $0.29 per dose, with the total per-dose cost (including the injection pen) around $5. The current high *prices* reflect patent protection, regulatory investment recovery, and a near-monopoly on a highly demanded product, not the inherent cost of production.

This gap will eventually close. Semaglutide's patents expire in China, India, Brazil, and Canada in 2026. The precedent from statins where generic competition drove prices down by 95% within five years of patent expiration suggests what is likely to follow. US and EU patent protection extends until 2031, but compulsory licensing, parallel imports, and competitive pressure from tirzepatide and newer agents may exert downward pressure before then. [Rethinking Health: The Health Optimizer Disruption](https://www.rethinkx.com/publications/rethinkinghealth2026.en) projects generic HOT prices as low as $10 per month by the mid-2030s in most regions.

Manufacturing investment is also scaling dramatically which will drive the cost down. Novo Nordisk has invested $8 billion in precision fermentation facilities in Denmark. Eli Lilly has invested tens of billions since 2020, including a continuous manufacturing platform in Ireland that cuts production time from weeks to days. Both companies are responding to the commercial reality that global demand for these drugs will be extraordinary and production at scale further reduces unit costs.

So yes, these drugs are expensive today - especially if you lack insurance coverage in the US, but this is a temporary feature of a disruption in its early commercial phase, not a permanent characteristic of the technology. The trajectory is strongly toward affordability, and good policy choices focused on generic entry, compulsory licensing, or public investment in drug development can accelerate that trajectory substantially.

### **Explore the evidence...**

- The fundamental disconnect is between price and cost of manufacture. A study by researchers from Yale University, King's College Hospital, and Doctors Without Borders, published in JAMA Network Open, found that a one-month supply of semaglutide can be produced for between $0.89 and $4.73 — including a profit margin — against a US list price of nearly $1,000. A March 2026 University of Liverpool analysis went further, estimating that generic injectable semaglutide could be produced for as little as $28 to $140 per person per year following patent expiry. Current high prices reflect patent protection and monopoly pricing power, not the inherent cost of making the drug. 
    - [Read the Yale, King's College, and Doctors Without Borders study on semaglutide production costs, published in JAMA Network Open.](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2816824)
    - [Read the University of Liverpool analysis on how low semaglutide prices could fall following patent expiry.](https://www.medrxiv.org/content/10.64898/2026.03.04.26347508v1)

 

- The price trajectory of HOTs will follow the same pattern RethinkX has observed across every major technology disruption it has studied. As production scales, competition increases, and patents expire, costs fall rapidly and predictably along an experience curve. This is  a well-documented feature of how disruptive technologies evolve, and it is already happening with GLP-1 drugs as semaglutide patents expire in multiple major markets in 2026. 
    - [Understand the cost-capability improvement curves that drive technology disruption and why HOT prices will inevitably fall.](https://www.rethinkx.com/our-science/sebaframework/indepth)

 

### **Witness the transformation**

We are entering a new era of healthcare based on a categorically different kind of medicine whose purpose is not just to save us from illness, but to help us be the best version of ourselves.

The next generation of HOTs will trigger a multi-trillion-dollar global disruption, affecting dozens of industries across multiple sectors, driving a radical global improvement in health and wellness encompassing at least 1 billion people worldwide before 2040.

Optimizing well with advanced HOTs will soon become as important as eating well with nutritious foods. Nations, industries, and individuals that recognize this early and act decisively will be best positioned to capture the extraordinary benefits of this transformation.

[Learn more about the HOT disruption and its implications for health, society, and the economy.](https://www.rethinkx.com/health/homepage)

 

**Disclaimer**

The information provided in this FAQ is for general informational and educational purposes only and is not intended to constitute medical advice, diagnosis, or treatment. This content does not establish a doctor-patient relationship. The content regarding GLP-1 receptor agonists (or any other medical treatments) should not be used as a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment options. Never disregard professional medical advice or delay in seeking it because of something you have read here. The authors and publishers of this FAQ and related report make no representation or warranty, express or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any information presented. Reliance on any information provided here is solely at your own risk.

[View full post](https://www.rethinkx.com/faq-and-mythbusting/arent-hots-expensive)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "RethinkX"
  },
  "dateModified" : "2026-06-02T15:02:36.994Z",
  "datePublished" : "2026-06-02T15:02:36Z",
  "headline" : "Aren’t HOTs expensive?",
  "image" : {
    "@type" : "ImageObject",
    "height" : 60,
    "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
    "width" : 60
  },
  "mainEntityOfPage" : "https://www.rethinkx.com/faq-and-mythbusting/arent-hots-expensive",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "FAQ & Mythbusting"
  }
}
```